angelus:
I suggest you time would be well spent looking into why the deal between MSB and Cephalon (taken over by Teva) got International biotech Deal of the Year?
The reason why there are huge payments on completing milestones is ...why?
Many biotechs struggle to get through one set of clinical trials, MSB has many running concurrently.
At the very least it involves risk-minimisation.
Where is there evidence of MSB failing any clinical trials? Does it even look likely?
I'd suggest there is significant confidence in the players to that deal, and I suggest you stop conflating all bios into one. The devil is in the detail and understanding the difference between bios is critical.
manipulation rife on asx say researchers, page-15
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.025(2.67%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 96.5¢ | 94.0¢ | $1.231M | 1.291M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 94461 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 61151 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |